E. Braendle

APhase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted ReceptorTyrosine Kinase Inhibitor in Patients with Advanced SolidTumors

I. Judson, D. Sarker, S. Louie, 2008 .

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

I. Judson, D. Jadayel, J. D. de Bono, 2008, Clinical Cancer Research.

Serum concentrations of DKK‐1 decrease in patients with multiple myeloma responding to anti‐myeloma treatment

O. Sezer, D. Stover, M. Mieth, 2009, European journal of haematology.

Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma

M. Peters, O. Sezer, D. Stover, 2008, European journal of haematology.

Postoperative resorptive and excretory capacity of the ileal neobladder

R. Hautmann, L. Rinnab, M. Straub, 2005, BJU international.

A phase Ib/II, multicenter, open-label study of DSP-7888 dosing emulsion in combination with immune checkpoint inhibitors (CPI) nivolumab or pembrolizumab in adult patients (pts) with advanced solid tumors, including platinum-resistant ovarian cancer (PROC).

E. Braendle, Makoto Origuchi, Zhonggai Li, 2020 .